LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "treated pts" as a keyword



P1040 Comparative effectiveness of upadacitinib versus ustekinumab in patients with moderately to severely active Crohn’s disease: a matching-adjusted indirect comparison

Sign Up to like & get
recommendations! Published in 2024 at "Journal of Crohn's and Colitis"

DOI: 10.1093/ecco-jcc/jjad212.1170

Abstract: Upadacitinib (UPA), an oral Janus kinase inhibitor, and ustekinumab (UST), a parenteral IL 12/23 antagonist, are effective treatments for moderately to severely active Crohn’s Disease (CD). In the absence of head-to-head data, a placebo (PBO)-anchored… read more here.

Keywords: moderately severely; upa ust; response; treated pts ... See more keywords

An independent, multi-center analysis of the post-approval utilization and efficacy of pacritinib and momelotinib in patients with myelofibrosis

Sign Up to like & get
recommendations! Published in 2025 at "Blood"

DOI: 10.1182/blood-2025-5600

Abstract: Introduction JAK inhibition is the basis of treatment for most patients (pts) with myelofibrosis (MF). Early JAK inhibitors (ruxolitinib (RUX) and fedratinib) result in myelosuppression that often exacerbates disease-related anemia and thrombocytopenia. The FDA-approval of… read more here.

Keywords: mom; mom treated; pac treated; treated pts ... See more keywords

Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.

Sign Up to like & get
recommendations! Published in 2019 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2019.37.15_suppl.4012

Abstract: 4012 Background: NIVO monotherapy (mono) is approved for sorafenib (SOR)-treated pts with HCC based on data from CheckMate 040 (NCT01658878), which reported an objective response rate (ORR) of 14% and median overall survival (mOS) of… read more here.

Keywords: ipi; treated pts; nivo ipi; checkmate 040 ... See more keywords

Angiogenic and immunomodulatory biomarkers in axitinib-treated patients (pts) with advanced renal cell carcinoma (aRCC).

Sign Up to like & get
recommendations! Published in 2019 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2019.37.7_suppl.614

Abstract: 614 Background: Axitinib (axi) is approved for 2nd-line treatment of aRCC. In AXIS trial, median progression-free survival (PFS) was significantly longer in axi- vs sorafenib (sor)-treated pts (hazard ratio [HR] 0.67, 95% CI 0.54–0.81, P read more here.

Keywords: axi sor; axi; treated pts; angiogenic immunomodulatory ... See more keywords